Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.

Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Eckhardt SG, Pitts TM.

BMC Cancer. 2018 Feb 5;18(1):136. doi: 10.1186/s12885-018-4036-z.

2.

Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.

Nijsen MJMA, Wu F, Bansal L, Bradshaw-Pierce E, Chan JR, Liederer BM, Mettetal JT, Schroeder P, Schuck E, Tsai A, Xu C, Chimalakonda A, Le K, Penney M, Topp B, Yamada A, Spilker ME.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):135-146. doi: 10.1002/psp4.12282. Epub 2018 Feb 1. Review.

3.

Correction to "Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure".

Lanier M, Pickens J, Bigi SV, Bradshaw-Pierce EL, Chambers A, Cheruvallath ZS, Cole D, Dougan DR, Ermolieff J, Gibson T, Halkowycz P, Hirokawa A, Ivetac A, McBride C, Miura J, Nunez E, Sabat M, Tyhonas J, Wang H, Wang X, Swann S.

ACS Med Chem Lett. 2017 Nov 8;8(12):1341. doi: 10.1021/acsmedchemlett.7b00457. eCollection 2017 Dec 14.

4.

Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure.

Lanier M, Pickens J, Bigi SV, Bradshaw-Pierce EL, Chambers A, Cheruvallath ZS, Cole D, Dougan DR, Ermolieff J, Gibson T, Halkowycz P, Hirokawa A, Ivetac A, Miura J, Nunez E, Sabat M, Tyhonas J, Wang H, Wang X, Swann S.

ACS Med Chem Lett. 2017 Feb 8;8(3):316-320. doi: 10.1021/acsmedchemlett.6b00481. eCollection 2017 Mar 9. Erratum in: ACS Med Chem Lett. 2017 Nov 08;8(12 ):1341.

5.

Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies.

Spilker ME, Chen X, Visswanathan R, Vage C, Yamazaki S, Li G, Lucas J, Bradshaw-Pierce EL, Vicini P.

Clin Cancer Res. 2017 Feb 15;23(4):1080-1090. doi: 10.1158/1078-0432.CCR-16-1164. Epub 2016 Aug 22.

6.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.

Oncotarget. 2016 Aug 2;7(31):50290-50301. doi: 10.18632/oncotarget.10366.

7.

Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.

Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S.

Invest New Drugs. 2016 Apr;34(2):176-83. doi: 10.1007/s10637-015-0316-5. Epub 2015 Dec 30.

8.

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.

Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG.

Front Pharmacol. 2015 Jun 16;6:120. doi: 10.3389/fphar.2015.00120. eCollection 2015.

9.

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S.

PLoS One. 2014 Nov 17;9(11):e113037. doi: 10.1371/journal.pone.0113037. eCollection 2014.

10.

Evidence of GnRH antagonist escape in obese women.

Roth LW, Bradshaw-Pierce EL, Allshouse AA, Lesh J, Chosich J, Bradford AP, Polotsky AJ, Santoro N.

J Clin Endocrinol Metab. 2014 May;99(5):E871-5. doi: 10.1210/jc.2013-3598. Epub 2014 Mar 20.

11.

Luteal phase dynamics of follicle-stimulating and luteinizing hormones in obese and normal weight women.

Roth LW, Allshouse AA, Bradshaw-Pierce EL, Lesh J, Chosich J, Kohrt W, Bradford AP, Polotsky AJ, Santoro N.

Clin Endocrinol (Oxf). 2014 Sep;81(3):418-25. doi: 10.1111/cen.12441. Epub 2014 Mar 20.

12.

Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.

Pitts TM, Davis SL, Eckhardt SG, Bradshaw-Pierce EL.

Pharmacol Ther. 2014 May;142(2):258-69. doi: 10.1016/j.pharmthera.2013.12.010. Epub 2013 Dec 19. Review.

PMID:
24362082
13.

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.

Palsson S, Hickling TP, Bradshaw-Pierce EL, Zager M, Jooss K, O'Brien PJ, Spilker ME, Palsson BO, Vicini P.

BMC Syst Biol. 2013 Sep 28;7:95. doi: 10.1186/1752-0509-7-95.

14.

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.

Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG.

Front Pharmacol. 2013 Mar 28;4:35. doi: 10.3389/fphar.2013.00035. eCollection 2013.

15.

Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer.

Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG.

Front Pharmacol. 2013 Mar 22;4:22. doi: 10.3389/fphar.2013.00022. eCollection 2013.

16.

Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.

Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD.

PLoS One. 2013;8(3):e58089. doi: 10.1371/journal.pone.0058089. Epub 2013 Mar 8.

17.

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG.

Clin Cancer Res. 2012 Feb 15;18(4):1051-62. doi: 10.1158/1078-0432.CCR-11-1507. Epub 2011 Dec 15.

18.

Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.

Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hasebroock KM, Pitts TM, Diamond JR, Fletcher GC, Bray MR, Eckhardt SG.

Clin Cancer Res. 2010 Jun 1;16(11):2989-2998. doi: 10.1158/1078-0432.CCR-10-0325. Epub 2010 Apr 20.

19.

A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.

Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, Hall T, Johnston A, Murphy M, Nemirovskiy O, Ogawa S, Pegg L, Pelc M, Prinsen M, Schnute M, Wendling J, Wene S, Weinberg R, Wittwer A, Zweifel B, Masferrer J.

J Pharmacol Exp Ther. 2010 Jul;334(1):310-7. doi: 10.1124/jpet.110.165845. Epub 2010 Apr 14.

PMID:
20392816
20.

Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice.

Serkova NJ, Renner B, Larsen BA, Stoldt CR, Hasebroock KM, Bradshaw-Pierce EL, Holers VM, Thurman JM.

Radiology. 2010 May;255(2):517-26. doi: 10.1148/radiol.09091134. Epub 2010 Mar 23.

21.

Oncologic imaging end-points for the assessment of therapy response.

Serkova NJ, Garg K, Bradshaw-Pierce EL.

Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):36-53. Review.

PMID:
19149687
22.

Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.

Bradshaw-Pierce EL, Steinhauer CA, Raben D, Gustafson DL.

Mol Cancer Ther. 2008 Sep;7(9):3006-17. doi: 10.1158/1535-7163.MCT-08-0370.

23.

In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation.

Zhang Y, Bradshaw-Pierce EL, Delille A, Gustafson DL, Anchordoquy TJ.

J Pharm Sci. 2008 Jan;97(1):237-50.

PMID:
17721944
24.

A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.

Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL.

Clin Cancer Res. 2007 May 1;13(9):2768-76.

25.

Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing.

Gustafson DL, Bradshaw-Pierce EL, Merz AL, Zirrolli JA.

J Pharmacol Exp Ther. 2006 Aug;318(2):872-80. Epub 2006 Apr 27.

PMID:
16644900

Supplemental Content

Loading ...
Support Center